```html

Opsoclonus‑Myoclonus Syndrome (OMS) – A Complete Patient Guide

Overview

Opsoclonus‑myoclonus syndrome (OMS) is a rare neurological disorder characterized by two hallmark features:

• Opsoclonus – rapid, involuntary, multidirectional eye movements that look like “dancing eyes.”
• Myoclonus – sudden, brief jerks of the limbs or trunk.

Patients often experience additional problems such as ataxia (loss of coordination), speech disturbances, and severe sleep‑related behavioral changes.

Who it affects

• Children: Approximately 70‑80 % of cases occur in children, most often between ages 6 months and 3 years.
• Adults: The remainder are adults, with a slight female predominance (≈55 %).

Prevalence

OMS is exceedingly uncommon, with an estimated incidence of 1‑2 cases per 1 million children per year in the United States [1] Mayo Clinic. The exact prevalence in adults is unknown but is thought to be lower than in children.

Symptoms

The clinical picture of OMS can evolve over days to weeks. Below is a comprehensive list of symptoms, grouped by system.

Neurologic

• Opsoclonus – chaotic, conjugate eye movements in all directions, no inter‑saccadic pause.
• Myoclonus – brief, shock‑like jerks affecting arms, legs, trunk, or face; often worse when at rest.
• Ataxia – unsteady gait, difficulty walking in a straight line, frequent stumbling.
• Hypotonia – decreased muscle tone, especially in infants.
• Speech/language problems – slurred speech (dysarthria) or language regression.
• Seizures – uncommon but reported in up to 10 % of pediatric cases.

Behavioral & Cognitive

• Sleep disturbances (insomnia, frequent night waking).
• Irritability, mood swings, or episodes of “autistic‑like” behavior.
• Learning difficulties and reduced attention span in school‑age children.

Systemic (when OMS is paraneoplastic)

• Weight loss, fever, or night sweats (often due to underlying tumor).
• Enlarged lymph nodes or abdominal mass (particularly neuroblastoma in children).

Causes and Risk Factors

OMS is considered a paraneoplastic or post‑infectious autoimmune disorder. The immune system mistakenly attacks parts of the brain that control eye movements and muscle tone.

Paraneoplastic OMS

• Children: >50 % are associated with neuroblastoma, a tumor of the adrenal glands or sympathetic nervous system.
• Adults: Frequently linked to small‑cell lung carcinoma, breast cancer, ovarian teratoma, or Hodgkin lymphoma.

Post‑infectious OMS

Viral or bacterial infections can trigger autoimmune cross‑reactivity. Reported precipitants include:

• Enterovirus (e.g., Coxsackie)
• Varicella‑zoster virus
• Epstein–Barr virus
• Mycoplasma pneumoniae

Other risk factors

• Genetic predisposition to autoimmunity (e.g., family history of autoimmune disease).
• Recent vaccinations (extremely rare; benefits of immunization far outweigh the risk).

Diagnosis

Diagnosing OMS requires a combination of clinical observation, exclusion of other disorders, and specific investigations.

Clinical Assessment

• Detailed neurologic exam focusing on eye movements, myoclonus, and coordination.
• Developmental assessment in children.

Laboratory Tests

• Serum and CSF autoantibodies – anti‑Hu, anti‑Ri, anti‑Yo, and anti‑NMDAR have been detected in some cases.
• Complete blood count, ESR, CRP to evaluate inflammation.
• Infectious work‑up: PCR or serology for viral agents when a post‑infectious trigger is suspected.

Imaging

• MRI of the brain – usually normal; may show mild cerebellar or brainstem changes.
• Whole‑body imaging for tumor search –
  • Infants/children: abdominal & pelvic ultrasound or MRI, MIBG (metaiodobenzylguanidine) scan for neuroblastoma.
  • Adults: CT chest/abdomen/pelvis, PET‑CT if cancer is suspected.

Electrodiagnostic Studies

• EEG – often normal but can help rule out seizures.
• EMG – may demonstrate brief motor bursts confirming myoclonus.

Diagnostic Criteria (adapted from NIH/CDC)

1. Presence of opsoclonus plus myoclonus.
2. At least one additional feature (ataxia, behavioral change, or speech disorder).
3. Exclusion of other neurologic diseases.
4. Evidence of an underlying trigger (tumor, infection, or immunologic marker) if possible.

Treatment Options

Early treatment improves neurological outcome and reduces the risk of permanent disability.

Immunotherapy – First‑line

• Corticosteroids (e.g., methylprednisolone 30 mg/kg IV for 3‑5 days, then oral taper). Reduces inflammation quickly.
• Intravenous immunoglobulin (IVIG) – 2 g/kg divided over 2‑5 days; beneficial especially in children.
• Plasma exchange (PLEX) – 5‑7 exchanges over 2 weeks; used when steroids/IVIG insufficient.

Second‑line / Maintenance Immunosuppression

• Rituximab – anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks.
• Mycophenolate mofetil – 600‑1200 mg/m² twice daily.
• Cyclophosphamide – reserved for refractory disease.

Treatment of Underlying Tumor (if present)

Oncologic surgery, chemotherapy, or radiotherapy as indicated. Tumor removal often leads to rapid neurologic improvement [2] NIH.

Symptomatic Medications

• Clonazepam or valproic acid for myoclonus.
• Physical therapy–guided antispastic agents (e.g., baclofen) for severe muscle tone abnormalities.

Rehabilitation & Supportive Care

• Physical, occupational, and speech therapy to address ataxia, fine‑motor deficits, and language regression.
• Behavioral therapy or counseling for mood and sleep disturbances.

Living with Opsoclonus‑Myoclonus Syndrome

While OMS can be disabling, many families achieve functional independence with a multidisciplinary approach.

Daily Management Tips

• Structured routine – predictable schedule for therapy, medication, meals, and sleep improves behavior.
• Safe environment – use padded flooring and guardrails; avoid high‑stairs for children with ataxia.
• Vision aids – eye‑patches or tinted glasses may reduce visual overstimulation.
• Assistive devices – gait belts, walkers, or weighted vests can enhance stability.
• School accommodations – individualized education plan (IEP) for extra time, physical therapy breaks, and quiet workspaces.
• Family education – teaching caregivers to recognize early relapse signs helps prompt treatment.

Emotional & Psychological Support

• Connect with support groups (e.g., OPS Support Network, RareDiseaseInfo.org).
• Consider counseling for anxiety or depressive symptoms common in chronic neurological disease.

Follow‑up Schedule

Most neurologists recommend:

• Every 1‑2 months during active treatment.
• Every 3‑6 months once stable, with repeat imaging for tumor surveillance in children.

Prevention

Because OMS is primarily autoimmune, true primary prevention is limited. However, several strategies may lower risk or aid early detection.

• Prompt evaluation of unexplained eye movement abnormalities in infants and adults.
• Early tumor screening in high‑risk age groups (e.g., abdominal ultrasound for infants with opsoclonus).
• Vaccination – maintains overall immune health; no credible evidence links routine vaccines to OMS.
• Infection control – timely treatment of viral or bacterial infections may reduce post‑infectious autoimmune activation.

Complications

If OMS is not treated promptly, the following complications may arise:

• Permanent cerebellar damage leading to chronic ataxia.
• Neurocognitive deficits (learning disabilities, IQ reduction).
• Behavioral disorders such as autism‑spectrum‑like features.
• Physical injuries from falls or uncontrolled jerks.
• In children with associated neuroblastoma, delayed tumor diagnosis can worsen oncologic prognosis.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Opsoclonus‑Myoclonus Syndrome. Updated 2023. https://www.mayoclinic.org
2. National Institutes of Health. Paraneoplastic Neurologic Disorders. 2022. https://www.ninds.nih.gov
3. Cleveland Clinic. Opsoclonus‑Myoclonus Syndrome (OMS). 2024. https://my.clevelandclinic.org
4. World Health Organization. Neuroblastoma Fact Sheet. 2023. https://www.who.int
5. J. H. Lang, et al. “Opsoclonus‑Myoclonus: Clinical features and treatment outcomes in pediatric patients.” *Journal of Pediatric Neurology*, 2022; 20(3): 145‑156.

```